FindTrial
Sign In

the efficacy and safety of high dose intravenous vitamin C in the treatment of novel coronavirus pneumonia (COVID-19): a prospective, randomize, controlled trial

the efficacy and safety of high dose intravenous vitamin C in the treatment of novel coronavirus pneumonia (COVID-19): a prospective, randomize, controlled trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000032400
Enrollment
Unknown
Registered
2020-04-27
Start date
2020-01-01
Completion date
Unknown
Last updated
2020-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

HDIVC group:100mg/kg/day
Control group:normal saline

Sponsors

Rujin Hospital, Shanghai Jiao Tong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: With fever, respiratory tract and other symptoms, imaging examination showed pneumonia

Exclusion criteria

Exclusion criteria: 1. age<18 years; 2. In the processing of treatment of tumor; 3. in the period of pregnant or lactation; 4. known kidney stone; 5. known allergy to vitamin C; 6. involved in other clinical trial; 7.refuse to signed the informed consent.

Design outcomes

Primary

MeasureTime frame
C-reactive protein;ESR;existence of SIRS;—

Secondary

MeasureTime frame
CD4+ lymphocyte counts;lymphocyte count;PaO2/FiO2 indicator;total bilirubin;cTNI;APPT;D-D dimer;LDH;CK;ratio of turning severe type;urine crystal;—

Countries

China

Contacts

Public ContactEnqiang Mao

Emergency department of Rujin Hospital, Shanghai Jiao Tong University School of Medicine

maoeq@yeah.net+86 13501747906

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026